PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsalzheimer disease
MeSH D000544 - alzheimer disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D003704:Dementia
$
Success rate
D024801:Tauopathies
0 Companies
0 Drugs
Success rate
D000544: 
Alzheimer disease
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaMemantine Memantine  2011-10-25   
Rivastigmine Rivastigmine Teva  2009-04-17   
MylanDonepezil Donepezil  2011-05-31   
Galantamine Galantamine  2009-05-29   
Memantine Memantine Mylan  2013-04-21   
Rivastigmine Rivastigmine  2018-06-20   
Johnson & JohnsonGalantamine Razadyne  2001-02-28   
CiplaDonepezil Donepezil  2011-05-31   
Lupin ResearchDonepezil Donepezil  2015-10-30   
Memantine Memantine  2015-04-10   
SandozDonepezil Donepezil  2011-05-31   
Galantamine Galantamine  2009-06-22   
Rivastigmine Rivastigmine Sandoz  2009-12-10   
Rivastigmine Exelon  2007-07-06   
NovartisRivastigmine Exelon  2000-04-21   
Rivastigmine Prometax  1998-12-03   
3MRivastigmine Rivastigmine 3M Health Care Ltd  2014-04-03   
Bausch Health CompaniesSelegiline Zelapar  2006-06-14   
AllerganMemantine Namenda  2005-04-18 $16.2 M Q2/19-Q1/20 
Donepezil Donepezil  2015-12-17   
Galantamine Galantamine  2008-12-15   
Memantine Nemdatine  2013-04-22   
Rivastigmine Rivastigmine  2008-01-08   
Rivastigmine Rivastigmine Actavis  2011-06-16   
1
2
3
4
5
6
...
9
>
Clinical Trials
Historical Success Rate
Phase 1
64%
74/115
Phase 2
45%
71/159
Phase 3
33%
42/126
Approved: 12Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Mylan
Johnson & Johnson
Novartis
1
2
3
4
5
6
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use